Munich - Delayed Quote EUR

Oryzon Genomics SA (ORN.MU)

比較
1.4480
0.0000
(0.00%)
收市：January 30 at 8:17:23 AM GMT+1
全部 全部 最愛 文字 統計資料 技術分析 Fibonacci 標示 線條
正在載入 ORN.MU 圖表

最新新聞: ORN.MU

更多內容
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting

ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting
GlobeNewswire 3 days ago
ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome
GlobeNewswire 7 days ago
ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor

ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor
GlobeNewswire 9 days ago
ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat in Combination With Venetoclax and Azacitidine Clinical Trial in First Line Acute Myeloid Leukemia

ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat in Combination With Venetoclax and Azacitidine Clinical Trial in First Line Acute Myeloid Leukemia
GlobeNewswire 17 days ago
ORYZON to Provide Corporate Progress Updates at Several Events in January-February

ORYZON to Provide Corporate Progress Updates at Several Events in January-February
GlobeNewswire 20 days ago
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat

ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
GlobeNewswire last month
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024
GlobeNewswire 3 months ago
ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder
GlobeNewswire 3 months ago
ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress

ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress
GlobeNewswire 4 months ago
ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder

ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder
GlobeNewswire 4 months ago
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia

ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia
GlobeNewswire 4 months ago
更多內容

相關股票代號

INNMF Amplia Therapeutics Limited
0.0450
0.00%
 
DRTS Alpha Tau Medical Ltd.
3.8000
+4.11%
 
RZLT Rezolute, Inc.
5.21
+2.96%
 
CLSD Clearside Biomedical, Inc.
0.9450
+2.75%
 
ABEO Abeona Therapeutics Inc.
5.47
+0.37%
 
ONC BeiGene, Ltd.
226.89
+0.08%
 
BCAB BioAtla, Inc.
0.4740
+2.35%
 
COEP Coeptis Therapeutics Holdings, Inc.
12.81
+3.39%
 
EYPT EyePoint Pharmaceuticals, Inc.
8.05
+4.14%
 
VOR Vor Biopharma Inc.
1.3900
+0.72%